Skip to main content

Advertisement

SpringerLink
Log in

Modern approaches to treating chronic myelogenous leukemia

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Over the past decade, the treatment of chronic myelogenous leukemia (CML) has gone through significant advances. Once an invariably fatal disease without stem cell transplant, it has since become one of the most manageable hematologic malignancies with good long-term outcomes. However, patients are not cured and require life-long treatment, and unfortunately, some of these patients develop resistant disease that progresses despite our best treatments. As our understanding of CML continues to grow, the repertoire of drugs available for successful treatment also increases. The following review discusses the current and future therapies for CML.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Faderl S, Talpaz M, Estrov Z, et al.: The biology of chronic myeloid leukemia. N Engl J Med 1999, 341:164–172.

    Article  PubMed  CAS  Google Scholar 

  2. Kantarjian H, Sawyers C, Hochhaus A, et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645–652.

    Article  PubMed  CAS  Google Scholar 

  3. O’Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994–1004.

    Article  PubMed  CAS  Google Scholar 

  4. Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079–1082.

    Article  PubMed  CAS  Google Scholar 

  5. Deininger MW, Goldman JM, Melo JV: The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343–3356.

    PubMed  CAS  Google Scholar 

  6. Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031–1037.

    Article  PubMed  CAS  Google Scholar 

  7. Sawyers CL, Hochhaus A, Feldman E, et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530–3539.

    Article  PubMed  CAS  Google Scholar 

  8. Druker BJ, Guilhot F, O’Brien SG, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408–2417.

    Article  PubMed  CAS  Google Scholar 

  9. Hochhaus A, Druker BJ, Larson R, et al.: IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed CML in chronic phase treated with imatinib [abstract 25]. Blood 2007, 110:15a.

    Google Scholar 

  10. Gorre ME, Mohammed M, Ellwood K, et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876–880.

    Article  PubMed  CAS  Google Scholar 

  11. Shah NP, Tran C, Lee FY, et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399–401.

    Article  PubMed  CAS  Google Scholar 

  12. Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531–2541.

    Article  PubMed  CAS  Google Scholar 

  13. Stone R, Kantarjian H, Baccarani M, et al.: Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013) [abstract]. Blood 2007, 110:734.

    Google Scholar 

  14. Kantarjian HM, Rousselot P, Pasquini R, et al.: Dasatinib or high-dose imatinib for patients with chronic phase CML resistant to standard dose imatinib: 2-year follow up data from START-R [abstract 736]. Blood 2007, 110:226a.

    Google Scholar 

  15. Guilhot F, Apperley JF, Kim D, et al.: Efficacy of dasatinib in patients with accelerated phase CML with resistance or intolerance to imatinib: 2 year follow up data from START-A [abstract 470]. Blood 2007, 110:145a.

    Google Scholar 

  16. Gambacorti C, Cortes J, Kim D, et al.: Efficacy and safety of dasatinib in patients with CML in blast crisis whose disease is resistant or intolerant to imatinib: 2 year follow up data from the START program [abstract 472]. Blood 2007, 110:145a.

    Google Scholar 

  17. Bristol-Myers Squibb: Clinical study report for study CA180-034. Available at http://ctr.bms.com/ctd/InitTrialDetailAction.do?pnum=CA180-034. Accessed May 5, 2008.

  18. Atallah EL, Kantarjian H, O’Brien S, et al.: Use of dasatinib in patients with previously untreated CML in chronic phase [ASCO abstract]. J Clin Oncol 2007, 25(18S):7005.

    Google Scholar 

  19. Golemovic M, Verstovsek S, Giles F, et al.: AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukaemia. Clin Cancer Res 2005, 11:4941–4947.

    Article  PubMed  CAS  Google Scholar 

  20. O’Hare T, Walters DK, Stoffregen EP, et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500–4505.

    Article  PubMed  CAS  Google Scholar 

  21. Kantarjian H, Giles F, Wunderle L, et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542–2551.

    Article  PubMed  Google Scholar 

  22. National Cancer Institute: FDA approval for nilotinib. Available at http://www.cancer.gov/cancertopics/druginfo/fda-nilotinib. Accessed June 3, 2008.

  23. Le Coutre P, Ottman OG, Giles F, et al.: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or — intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008, 111:1834–1839.

    Article  PubMed  Google Scholar 

  24. Cortes J, O’Brien S, Jabbour E, et al.: Efficacy of nilotinib (AMN107) in patients with newly diagnosed, previously untreated Philadelphia chromosome positive CML in early chronic phase [abstract]. Blood 2007, 110:29.

    Article  Google Scholar 

  25. Puttini M, Coluccia AM, Boschelli F, et al.: In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL+ neoplastic cells. Cancer Res 2006, 66:11314–11322.

    Article  PubMed  CAS  Google Scholar 

  26. Gambacorti-Passerini C, Brummendorf T, Kantarjian H, et al.: Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib [ASCO abstract]. J Clin Oncol 2007, 25(18S):7006.

    Google Scholar 

  27. Cortes J, Brummendorf T, Kantarjian H, et al.: Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph+ chronic myelogenous leukemia (CML) [abstract]. Blood 2007, 110:733.

    Article  Google Scholar 

  28. Gambacorti-Passerini C, Kantarjian H, Brummendorf T, et al.: Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph+ All [abstract]. Blood 2007, 110:473.

    Article  Google Scholar 

  29. Naito H, Kimura S, Nakaya Y, et al.: In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations. Leuk Res 2006, 30:1443–1446.

    Article  PubMed  CAS  Google Scholar 

  30. Kantarjian J, Cortes J, Le Coutre P, et al.: A phase I study of INNO-406 in patients with advanced Ph+ leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors [abstract]. Blood 2007, 110:469.

    Article  Google Scholar 

  31. Yokota A, Kimura S, Masuda S, et al.: INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007, 109:306–314.

    Article  PubMed  CAS  Google Scholar 

  32. Shah N, Kasap C, Paquette R, et al.: Targeting drug resistant CML and Ph+ALL with the spectrum selective protein kinase inhibitor XL228 [abstract 474]. Blood 2007, 110:146a.

    Google Scholar 

  33. Nigg EA: Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2001, 2:21–32.

    Article  PubMed  CAS  Google Scholar 

  34. Giles FJ, Cortes J, Jones D, et al.: MK-0457, a novel kinase inhibitor, is active in patients with CML or ALL with the T315I mutation. Blood 2007, 109:500–502.

    Article  PubMed  CAS  Google Scholar 

  35. Paquette L, Shah NP, Sawyers CL, et al.: PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL [abstract 1030]. Blood 2007, 110:312a.

    Google Scholar 

  36. Tauchi T, Akahane D, Nunoda K, et al.: Combined effects of a Pan-Aurora kinase inhibitor MK-0457 and dasatinib against T315I mutant form of BCR-ABL: in vitro and in vivo studies [abstract]. Blood 2007, 110:805.

    Google Scholar 

  37. Strauss A, Chu S, Holyoake T, et al.: Effective induction of apoptosis in chronic myeloid leukemia CD34+ cells by the histone deacetylase inhibitor LAQ824 in combination with imatinib [abstract]. Blood 2007, 110:1031.

    Google Scholar 

  38. Copland M, Pellicano F, Richmond L, et al.: BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008, 111:2843–2853.

    Article  PubMed  CAS  Google Scholar 

  39. Pinilla-Ibarz J, Cathcart K, Scheinberg D: CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Rev 2000, 14:111–120.

    Article  PubMed  CAS  Google Scholar 

  40. Bocchia M, Korontsvit T, Xu Q, et al.: Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996, 87:3587–3592.

    PubMed  CAS  Google Scholar 

  41. Pinilla-Ibarz J, Cathcart K, Korontsvit T, et al.: Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000, 95:1781–1787.

    PubMed  CAS  Google Scholar 

  42. Cathcart K, Pinilla-Ibarz J, et al.: A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004, 103:1037–1042.

    Article  PubMed  CAS  Google Scholar 

  43. Bocchia M, Gentili S, Abruzzese E, et al.: Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005, 365:657–662.

    PubMed  CAS  Google Scholar 

  44. Rojas JM, Knight K, Wang J, Clark RE: Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 2007, 21:2287–2295.

    Article  PubMed  CAS  Google Scholar 

  45. Pinilla-Ibarz J, May RJ, Korontsvit T, et al.: Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia 2006, 20:2025–2033.

    Article  PubMed  CAS  Google Scholar 

  46. May RJ, Dao T, Pinilla-Ibarz J, et al.: Peptide epitopes from the Wilms’ tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 2007, 1:4547–4555.

    Article  Google Scholar 

  47. Maslak P, Daao T, Gomez M, et al.: A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. Leukemia 2008 Feb 7 (Epub ahead of print).

  48. Smith B, Kasamon YL, Miller CB, et al.: K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) patients (pts) with residual disease on imatinib mesylate (IM) [ASCO abstract]. J Clin Oncol 2006, 24(18S):6509.

    Google Scholar 

  49. Marin D, Mauro M, Goldman J, et al.: Preliminary results from a phase 2 trial of AG-858, an autologous heat shock protein-peptide vaccine, in combination with imatinib in patients with chronic phase chronic myeloid leukemia (CML) resistant to prior imatinib monotherapy [abstract]. Blood 2005, 10:1094.

    Google Scholar 

  50. Rezvani K, Yong AS, Mielke S, et al.: Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008, 111:236–242.

    Article  PubMed  CAS  Google Scholar 

  51. Rusakiewicz S, Molldrem JJ: Immunotherapeutic peptide vaccination with leukemia-associated antigens. Curr Opin Immunol 2006, 18:599–604.

    Article  PubMed  CAS  Google Scholar 

  52. Oka Y, Tsuboi A, Elisseeva OA, et al.: WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers. Scientific WorldJournal 2007, 7:649–665.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Malignant Hematology, H. Lee Moffitt Cancer and Research Institute, 12902 Magnolia Drive, MRC 3E/3056H, Tampa, FL, 33612, USA

    Javier Pinilla-Ibarz

Authors
  1. Javier Pinilla-Ibarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Celeste Bello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Javier Pinilla-Ibarz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pinilla-Ibarz, J., Bello, C. Modern approaches to treating chronic myelogenous leukemia. Curr Oncol Rep 10, 365–371 (2008). https://doi.org/10.1007/s11912-008-0057-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-008-0057-0

Keywords

Search

Navigation